Rapha Global Corporation

Rapha Global Corporation is a biotechnology company headquartered in Irvine, California, specializing in the discovery and development of natural product-based therapeutics. The company leverages a proprietary platform that combines an extensive library of natural compounds with high-throughput screening technologies to identify novel drug candidates. Rapha Global's primary research focus spans oncology, inflammatory diseases, and metabolic disorders, aiming to transform traditional natural remedies into clinically validated pharmaceuticals. Their pipeline includes several pre-clinical programs, such as RGC-101 for solid tumors and RGC-102 for inflammatory conditions. In addition to its drug discovery efforts, the company maintains a presence in the high-end nutraceutical market, applying pharmaceutical-grade standards to its supplement offerings.